



# Coding Systemic Therapy



## Bladder Cancer Systemic Therapy



Chemotherapy	Subcategory
Carboplatin (Paraplatin)	Alkylating agent, Platinum analog
Cisplatin (Platinol, Platinol-AQ)	Alkylating agent, Platinum analog
Doxorubicin (Adriamycin)	Antitumor antibiotic
Gemcitabine (Gemzar, Gemcitabine Hydrochloride)	Antimetabolite
Methotrexate (Folex, Folex PFS, Mexate, Mexate AQ)	Antimetabolite
Thiotepa	Alkylating agent

Biological Response Modifiers	Subcategory
Atezolizumab* (Tecentriq, MPDL3208A)	Monoclonal antibody
Avelumab* (Bavencio) FDA approved 5/17	Monoclonal antibody
Bacillus Calmette-Guerin (BCG)	Immunotherapy active
Durvalumab* (Imfinzi) FDA approved 5/17	None
Nivolumab (Opdivo) FDA approved 2/17	braf inhibitor
Pembrolizumab (Keytruda) FDA approved 5/17	Monoclonal antibody

\* *PD-L1 inhibitors: interacts with the PD-1 protein on T cells*

### Common Regimens

Gemzar & Cisplatin

**MVAC:** Methotrexate, Vinblastine (Velban, Velsar), Doxorubicin & Cisplatin

Dose dense (DD)-MVAC

Adapted from the presentation "Coding Systemic Treatment" and used with permission of Mary B. Davidson, RN, BSN, MN, CTR